|
WO2015197874A2
|
|
Combination of cd95/cd95l inhibition and cancer immunotherapy
|
|
WO2015165973A1
|
|
Diagnostic anti-cd95l antibody
|
|
JP2015143270A
|
|
Fusion proteins forming trimers
|
|
JP2014218510A
|
|
Fusion proteins forming trimers
|
|
BR112015027249A2
|
|
cancer diagnosis method
|
|
US2015166633A1
|
|
Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof
|
|
US2010111969A1
|
|
Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
|
|
CA2910512A1
|
|
Tnfsf single chain molecules
|
|
EP2540740A2
|
|
Multimeric TNF receptors
|
|
AU2009231482A1
|
|
Binding agents directed against IL-4 receptor for the treatment of tumors, inflammatory and immunological disorders
|
|
US2009196868A1
|
|
Methods and compositions for preventing radiation-induced pneumonitis
|
|
EP2484691A1
|
|
TNF superfamily collectin fusion proteins
|
|
WO2008101671A2
|
|
Il-4 fc fusion proteins
|
|
WO2008003514A2
|
|
Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
|
|
EP2009022A1
|
|
Trimeric death ligands with enhanced activity (tenascin)
|
|
BRPI0713484A2
|
|
cytokine differential expression in human cancer
|
|
AU2007228943A1
|
|
Antibody specific for human IL-4 for the treament of cancer
|
|
EP1894940A1
|
|
TNF superfamily fusion proteins
|
|
US2007292389A1
|
|
Method for the Purification and Amplification of Tumoral Stem Cells
|
|
CA2520138A1
|
|
Improved fc fusion proteins
|
